APG Asset Management US Inc. Invests $346,000 in Hologic, Inc. (NASDAQ:HOLX)

APG Asset Management US Inc. purchased a new position in Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 4,800 shares of the medical equipment provider’s stock, valued at approximately $346,000.

A number of other institutional investors also recently made changes to their positions in HOLX. Benson Investment Management Company Inc. acquired a new stake in shares of Hologic during the fourth quarter valued at approximately $4,832,000. Principal Financial Group Inc. raised its holdings in shares of Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock valued at $19,547,000 after acquiring an additional 1,606 shares during the period. Clean Yield Group raised its holdings in shares of Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after acquiring an additional 7,266 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after acquiring an additional 800 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after acquiring an additional 238,222 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on HOLX. Stephens reiterated an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada dropped their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Morgan Stanley decreased their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a report on Monday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

Hologic stock opened at $59.31 on Thursday. The company has a market capitalization of $13.31 billion, a P/E ratio of 18.71, a P/E/G ratio of 2.14 and a beta of 0.82. The business has a 50 day moving average of $63.03 and a 200-day moving average of $71.87. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 1 year low of $57.38 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.